Senomyx's Fake Flavors - Human Embryonic Kidney 293 cells (HEK 293)

[link to youtu.be]

(((Cambells have ditched their ties with Senomyx i think)))

Senomyx, Inc. Turning the World Into Cannibals

Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage and ingredient supply industries, announced today that it has been notified by the Flavor and Extract Manufacturers Association (FEMA) that its sucralose enhancer, S2383, has been determined to be Generally Recognized As Safe (GRAS) under the provisions of the Federal Food, Drug and Cosmetic Act, administered by the United States Food and Drug Administration (FDA). S2383, which was discovered and developed by Senomyx, is an extremely effective enhancer of the high-intensity sweetener sucralose. The GRAS determination by FEMA allows S2383 to be incorporated into products in the U.S. and in numerous other countries.

[link to www.yahspeople.com]

Senomyx Announces Corporate Update and Second Quarter 2011 Financial Results.

Commercialization activities with Senomyx’s S6973 Sucrose Enhancer continue to draw interest from major food and beverage companies

New additions to Senomyx’s deep pipeline of flavor ingredients with competitive advantages:

* Recently discovered High Fructose Corn Syrup (HFCS) Enhancers enable up to a 33% reduction of HFCS while maintaining desired sweetness

* New Savory Flavors S9229 & S5456 receive GRAS (Generally Recognized As Safe) regulatory status, which allows commercialization & expands Senomyx’s offerings

Improved financial results from operations compared to 2010

SAN DIEGO--(BUSINESS WIRE)--Oct. 27, 2011--Senomyx, Inc. (NASDAQ: SNMX), a company focused on using proprietary taste receptor-based technologies to discover novel flavor ingredients for the food, beverage, and ingredient supply industries, today provided a corporate update and reported financial results for the third quarter ended September 30, 2011. Revenues were $7.1 million for the three months ended September 30, 2011, compared to $5.8 million for the three months ended September 30, 2010, a 22% increase. Revenues were $22.8 million for the nine months ended September 30, 2011, compared to $19.2 million for the nine months ended September 30, 2010, an increase of 19%. Net loss was $2.6 million for the three months ended September 30, 2011, compared to $3.7 million for the three months ended September 30, 2010, a 30% improvement. Net loss was $7.1 million for the nine months ended September 30, 2011, compared to $10.2 million for the three months ended September 30, 2010, a 31% improvement.

[link to www.businesswire.com]

Senomyx has 85 patents on file with the US Patent office and at least 70 of which cite their use of HEK (human embryonic kidney) cells.
[link to patft.uspto.gov]

This crap is going to be in so many things.